AAPL 238.8 3.8893% MSFT 445.64 2.5497% NVDA 126.645 6.9456% GOOGL 195.01 1.6683% GOOG 196.71 1.5173% AMZN 239.22 1.6141% META 679.365 2.9528% AVGO 203.53 0.6926% LLY 807.205 -0.1194% TSLA 393.3501 -0.9568% TSM 199.39 3.6816% V 337.31 0.828% JPM 266.12 0.1016% UNH 541.75 -0.3257% NVO 84.74 -3.1654% WMT 97.4648 0.0665% LVMUY 152.0 -4.252% XOM 108.17 -1.8154% LVMHF 765.0 -3.7433% MA 549.66 0.3689%
Last update at 2025-01-28T18:53:00Z
4 Stocks With Big Rebound Potential
Mon 15 Jan 24, 11:47 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 184.03M | 677.30M | 291.68M | 0.41M | -4.62300M |
| Minority interest | 1.48M | 1.12M | - | - | - |
| Net income | 143.40M | 507.36M | 214.31M | 0.37M | -4.48900M |
| Selling general administrative | 111.07M | 50.73M | 15.21M | 6.41M | 5.54M |
| Selling and marketing expenses | 38.92M | 24.44M | 14.95M | 5.90M | 4.65M |
| Gross profit | 366.90M | 777.05M | 331.90M | 18.42M | 10.66M |
| Reconciled depreciation | 32.66M | 1.71M | 2.96M | 2.11M | 2.16M |
| Ebit | 178.53M | 675.95M | 287.20M | -2.53500M | -7.22000M |
| Ebitda | 190.97M | 677.66M | 290.16M | -0.42800M | -5.05700M |
| Depreciation and amortization | 12.45M | 1.71M | 2.96M | 2.11M | 2.16M |
| Non operating income net other | - | 5.08M | -3.31600M | 0.06M | -0.50100M |
| Operating income | 178.53M | 675.95M | 290.16M | -0.42800M | -5.05700M |
| Other operating expenses | 437.47M | 316.63M | 131.55M | 32.96M | 26.41M |
| Interest expense | 5.50M | 6.21M | 0.35M | 2.17M | 0.00000M |
| Tax provision | 42.10M | 174.79M | 72.53M | 0.04M | 0.04M |
| Interest income | 5.50M | 1.35M | 1.53M | 0.84M | 0.43M |
| Net interest income | 5.50M | 1.35M | 1.53M | 0.84M | 0.43M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 42.10M | 174.79M | 72.53M | 0.04M | -1.06900M |
| Total revenue | 618.97M | 992.58M | 421.71M | 32.53M | 21.36M |
| Total operating expenses | 185.40M | 101.10M | 41.75M | 18.85M | 15.72M |
| Cost of revenue | 252.07M | 215.53M | 89.81M | 14.11M | 10.69M |
| Total other income expense net | 5.50M | 1.35M | 1.53M | 0.84M | 0.43M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 141.92M | 506.24M | 219.15M | -0.41100M | -5.60700M |
| Net income applicable to common shares | 143.40M | 507.36M | 214.31M | -0.41100M | -5.60700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1273.11M | 1386.05M | 1278.72M | 700.46M | 88.76M |
| Intangible assets | 143.05M | 150.64M | 35.91M | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 26.25M | 22.25M | -12.20600M | -16.49100M | 0.28M |
| Total liab | 139.82M | 116.18M | 112.84M | 131.07M | 5.98M |
| Total stockholder equity | 1136.10M | 1269.88M | 1165.88M | 569.39M | 82.78M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 49.10M | 58.35M | 36.69M | 62.72M | 3.61M |
| Common stock | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00200M |
| Capital stock | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00200M |
| Retained earnings | 633.17M | 801.00M | 657.60M | 150.88M | -63.42900M |
| Other liab | - | 17.46M | 0.79M | 0.39M | - |
| Good will | 22.05M | 143.03M | 50.90M | - | - |
| Other assets | 0.00000M | 26.56M | 912.63M | 44.54M | 0.25M |
| Cash | 97.47M | 79.51M | 164.89M | 87.43M | 11.96M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 73.02M | 116.18M | 112.84M | 131.07M | 5.98M |
| Current deferred revenue | 2.87M | 14.09M | 34.38M | 26.58M | 0.36M |
| Net debt | -82.56600M | -58.86800M | -143.61000M | -71.57200M | -9.28900M |
| Short term debt | 5.68M | 20.64M | 21.28M | 15.29M | 0.42M |
| Short long term debt | 1.18M | 20.64M | 21.28M | 15.02M | - |
| Short long term debt total | 14.91M | 20.64M | 21.28M | 15.85M | 2.68M |
| Other stockholder equity | 481.28M | 477.39M | 487.07M | 418.06M | 146.06M |
| Property plant equipment | - | 98.92M | 62.29M | 40.20M | 8.61M |
| Total current assets | 507.85M | 905.63M | 1074.46M | 615.73M | 76.77M |
| Long term investments | 444.01M | 339.03M | 507.01M | 132.50M | 42.82M |
| Net tangible assets | - | 973.01M | 1165.88M | 569.39M | 82.78M |
| Short term investments | 326.68M | 773.38M | 770.65M | 344.44M | 58.25M |
| Net receivables | 57.45M | 52.75M | 138.91M | 183.86M | 6.55M |
| Long term debt | 2.96M | - | - | - | - |
| Inventory | 5.83M | 4.28M | 12.21M | 16.49M | 0.28M |
| Accounts payable | 15.36M | 23.09M | 20.49M | 26.49M | 1.58M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 7.13M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.21M | -20.90300M | -0.75900M | 0.44M | 0.15M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.00300M | 0.00300M | 0.00200M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | 657.60M | 150.88M | -63.42900M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 32.03M | -233.63500M | 141.97M | -87.96600M | -36.80800M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 765.26M | 480.42M | 204.26M | 84.73M | 11.98M |
| Capital lease obligations | 11.10M | - | - | 0.83M | 2.68M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -261.31400M | -460.89900M | -289.93600M | -27.86400M | 3.27M |
| Change to liabilities | -25.33900M | -12.20600M | 108.57M | -0.04100M | 0.64M |
| Total cashflows from investing activities | -261.31400M | -546.54800M | -326.43800M | -29.04600M | 0.95M |
| Net borrowings | -1.06700M | -0.01100M | 15.02M | 15.02M | 15.02M |
| Total cash from financing activities | -77.14100M | 85.41M | 261.25M | 28.77M | 0.01M |
| Change to operating activities | -40.46700M | 19.76M | 11.12M | 0.23M | 0.62M |
| Net income | 141.92M | 506.24M | 214.31M | -0.41100M | -5.60700M |
| Change in cash | -85.38800M | 77.47M | 75.46M | 5.23M | 0.25M |
| Begin period cash flow | 164.89M | 87.43M | 11.96M | 6.74M | 6.49M |
| End period cash flow | 79.51M | 164.89M | 87.43M | 11.96M | 6.74M |
| Total cash from operating activities | 253.52M | 538.58M | 140.63M | 5.52M | -0.67500M |
| Issuance of capital stock | 0.00000M | 89.47M | 246.19M | 28.76M | - |
| Depreciation | 32.66M | 11.00M | 2.96M | 2.11M | 2.16M |
| Other cashflows from investing activities | - | -81.83700M | -1.37200M | -27.86400M | 3.27M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | -36.18100M |
| Change to account receivables | 68.64M | 42.30M | -178.48000M | -0.83900M | -1.97000M |
| Sale purchase of stock | -74.33700M | 89.57M | -0.06200M | -0.02100M | 0.01M |
| Other cashflows from financing activities | -1.76800M | -4.05900M | 15.12M | 0.04M | 0.01M |
| Change to netincome | 75.45M | 22.89M | 8.72M | 4.22M | 3.72M |
| Capital expenditures | 18.77M | 23.84M | 36.51M | 1.32M | 2.83M |
| Change receivables | - | 42.30M | -178.48000M | -0.83900M | -1.97000M |
| Cash flows other operating | - | 4.45M | -16.30800M | 0.38M | 0.09M |
| Exchange rate changes | - | - | - | - | -0.04400M |
| Cash and cash equivalents changes | - | 77.43M | 75.44M | 5.25M | 0.25M |
| Change in working capital | 2.00M | -2.67600M | -91.45100M | -0.91500M | -1.24400M |
| Stock based compensation | 32.64M | 15.88M | 8.16M | 3.21M | 2.30M |
| Other non cash items | 43.46M | 15.97M | 8.05M | 1.55M | 1.67M |
| Free cash flow | 234.75M | 514.73M | 104.12M | 4.20M | -3.50700M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FLGT Fulgent Genetics Inc |
0.07 0.40% | 17.48 | - | 7.94 | 2.15 | 0.55 | 0.74 | -4.3402 |
| TMO Thermo Fisher Scientific Inc |
-1.145 0.20% | 582.50 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-1.77 0.71% | 248.82 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
0.83 0.55% | 151.79 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
-7.28 1.70% | 420.24 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
4399 Santa Anita Avenue, El Monte, CA, United States, 91731
| Name | Title | Year Born |
|---|---|---|
| Mr. Ming Hsieh | Chairman & CEO | 1956 |
| Mr. Jian Xie | COO & Pres | 1966 |
| Mr. Paul Kim | Chief Financial Officer | 1967 |
| Dr. Han Lin Gao D.A.B.M.G., F.A.C.M.G., FACMG, M.D., Ph.D. | Chief Scientific Officer & Laboratory Director | 1967 |
| Ms. Natalie Prescott | VP of Legal & Deputy Gen. Counsel | NA |
| Ms. Doreen Ng | VP of Operations & Compliance and GM of Houston Office | NA |
| Mr. Jakub Sram | VP of Bus. Devel. & Sales | NA |
| Ms. Ellen Tsui | VP of HR | NA |
| Mr. Brandon Perthuis | Chief Commercial Officer | NA |
| Dr. Lawrence M. Weiss M.D. | Chief Medical Officer | 1957 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...